{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:32:05Z","timestamp":1773167525775,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,8,15]],"date-time":"2015-08-15T00:00:00Z","timestamp":1439596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute (CA)","doi-asserted-by":"publisher","award":["16512"],"award-info":[{"award-number":["16512"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharmaeuticals Canada"},{"name":"United States National Cancer Institute, Department of Health and Human Services Grants","award":["U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974, U10-CA180868, UG1-CA189867, U10-CA180822, U24-CA196067, U24-CA114732"],"award-info":[{"award-number":["U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974, U10-CA180868, UG1-CA189867, U10-CA180822, U24-CA196067, U24-CA114732"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s10549-015-3547-4","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T01:26:29Z","timestamp":1439515589000},"page":"353-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29"],"prefix":"10.1007","volume":"153","author":[{"given":"Judith-Anne W.","family":"Chapman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Margolese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen I.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois E.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Gelmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,15]]},"reference":[{"key":"3547_CR1","first-page":"889","volume":"9","author":"M Pollak","year":"1989","unstructured":"Pollak M, Polychronakos C, Guyda H (1989) Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9:889\u2013892","journal-title":"Anticancer Res"},{"issue":"8898","key":"3547_CR2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(94)92637-9","volume":"343","author":"CH Eijck van","year":"1994","unstructured":"van Eijck CH, Krenning EP, Bootsma A et al (1994) Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343(8898):640\u2013643","journal-title":"Lancet"},{"issue":"24","key":"3547_CR3","first-page":"6334","volume":"54","author":"G Weckbecker","year":"1994","unstructured":"Weckbecker G, Tolcsvai L, Stolz B et al (1994) Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7, 12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 54(24):6334\u20136337","journal-title":"Cancer Res"},{"issue":"27","key":"3547_CR4","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1200\/JCO.2010.33.7006","volume":"29","author":"KI Pritchard","year":"2011","unstructured":"Pritchard KI, Shepherd LE, Chapman JW et al (2011) A randomized trial of tamoxifen versus combined tamoxifen and octreotide lar therapy in the adjuvant treatment of early stage breast cancer in post-menopausal women: NCIC CTG MA.14. J Clin Oncol 29(27):3869\u20133876","journal-title":"J Clin Oncol"},{"key":"3547_CR5","doi-asserted-by":"crossref","unstructured":"Pollak MN, Chapman JAW, Pritchard KI, et al. (2010) Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. J Clin Oncol 28 (15S, pt I): 77s (Abstract)","DOI":"10.1200\/jco.2010.28.15_suppl.542"},{"key":"3547_CR6","unstructured":"Goss PE, Ingle JN, Pritchard KI, et al.; for the NCIC CTG MA.27 Study Investigators (2013). Exemestane versus Anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 A Randomized Controlled Phase III Trial. J Clin Oncol 31(11):1398\u20131404"},{"issue":"4","key":"3547_CR7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/djn014","volume":"100","author":"JW Chapman","year":"2008","unstructured":"Chapman JW, Meng D, Shepherd L et al (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100(4):252\u2013260","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3547_CR8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.5306\/wjco.v5.i5.1088","volume":"5","author":"JW Chapman","year":"2014","unstructured":"Chapman JW, Pritchard KI, Goss PE et al (2014) Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin Oncol 5(5):1088\u20131096","journal-title":"World J Clin Oncol"},{"issue":"9631","key":"3547_CR9","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/S0140-6736(08)60933-2","volume":"371","author":"J Cuzick","year":"2008","unstructured":"Cuzick J (2008) Primary endpoints for randomized trials of cancer therapy. Lancet Oncol 371(9631):2156\u20132158","journal-title":"Lancet Oncol"},{"issue":"9","key":"3547_CR10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","volume":"2","author":"M Pollak","year":"2012","unstructured":"Pollak M (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2(9):778\u2013790","journal-title":"Cancer Discov"},{"issue":"4","key":"3547_CR11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1078-0432.CCR-14-2056","volume":"21","author":"D Yee","year":"2015","unstructured":"Yee D (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21(4):667\u2013669","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3547-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3547-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T06:32:03Z","timestamp":1567060323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3547-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,15]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["3547"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3547-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,15]]}}}